Prospective observational study on safety and efficacy of combination therapy of inhaled corticosteroids and long-acting – beta 2 agonists bronchodilators in respiratory disease

Aim: To assess the effectiveness and safety of Long-acting beta 2 agonist bronchodilators combined with inhaled corticosteroids in the treatment of respiratory disorders. Objectives: A prospective observational study on the safety and efficacy of combination therapy of inhaled corticosteroids and long-acting beta 2 agonists bronchodilators in respiratory diseases. To evaluate the safety of combination therapy for respiratory diseases. To evaluate the negative impacts of the medications. To determine the effectiveness of a combination treatment for respiratory disorders. Method: A total of 200 cases were collected in the study and were followed for prospective study in Kim Sunshine Hospital, Secunderabad for 6 months. The following evaluation was made from the collected data. Results: A Total of 200 subjects were recruited for the research, consisting of 123 men and 77 women. When taking gender into account as a variable, It can be stated that males (61.5%) are treated with combination therapy (ICS and LABA) more often than females (38.5%) with respiratory disorders. The majority of patients were affected with COPD and Asthma (34% and 27.5%, respectively), while bronchitis and pleural effusion Patients are only 13% and 9.5% respectively. The combination of formoterol and budesonide was used most frequently (about 74.5%), while mometasone and formoterol were used the least frequently (9.5%). Combination therapy fully controlled 59% of the subjects, 22% of the subjects were cured, 17% of the subjects were relieved, and 2% of the subjects showed no change. Conclusion: From this study, we conclude that the effect of combinational therapy of inhaled corticosteroid and long-acting beta 2 agonist bronchodilators is more safe and effective in respiratory disease with minimum adverse drug reactions.